BWA
41
5
PG
45
2
CMA
42
2
FMC
43
3
GE
64
-3
AZO
48
5
IFF
45
3
QCOM
69
-2
MAS
58
-10
AAP
35
6
FOX
33
3
EXPD
45
2
DVA
68
-2
CMCSA
57
4
MKC
42
-9
EL
50
7
NVDA
56
2
DFS
53
6
RCL
57
-2
HRL
36
-2
BWA
41
5
PG
45
2
CMA
42
2
FMC
43
3
GE
64
-3
AZO
48
5
IFF
45
3
QCOM
69
-2
MAS
58
-10
AAP
35
6
FOX
33
3
EXPD
45
2
DVA
68
-2
CMCSA
57
4
MKC
42
-9
EL
50
7
NVDA
56
2
DFS
53
6
RCL
57
-2
HRL
36
-2
Financhill
Back

Aclaris Therapeutics 10K Form

Sell
26

ACRS
Aclaris Therapeutics

Last Price:
1.25
Seasonality Move:
-2.56%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ACRS News And Ratings

See the #1 stock for the next 7 days that we like better than ACRS

ACRS Financial Statistics

Sales & Book Value

Annual Sales: $31.25M
Cash Flow: $-7.2M
Price / Cash Flow: 0
Annual Sales: $2.22
Price / Book: 0.56

Profitability

EPS (TTM): -1.27000
Net Income (TTM): $-88.48M
Gross Margin: $13.17M
Return on Equity: -50.99%
Return on Assets: -38.95%

Aclaris Therapeutics Earnings Forecast

Key Aclaris Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 10 years for ACRS is 42.14%.
  • The Selling, General & Administrative Expenses for ACRS have been equal to 99.52% of Gross Profit Margin.
  • The Research & Development expenses have been 314.84% of Revenue.
  • The Net Earning history of ACRS is -283.15% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 5 years.

Aclaris Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: ACRS
CUSIP: 00461U
Website: aclaristx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.16
Quick Ratio: 3.86

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ACRS Technical Analysis vs Fundamental Analysis

Sell
26
Aclaris Therapeutics (ACRS) is a Sell

Is Aclaris Therapeutics a Buy or a Sell?